Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript November 6, 2024Amicus Therapeutics, Inc. beats earnings expectations.
Posts Tagged ‘NASDAQ:FOLD’
10 Best Guru Stocks To Buy Now
Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the right set of vehicles to either preserve or grow money...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15985 EPS, expectations were $-0.06. Amicus Therapeutics, Inc.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast.
20 Fastest Growing Biotech Companies in the US
In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.
15 Best Growth Stocks to Buy Under $25
In this article, we present 15 best growth stocks under $25.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Second Quarter 2023 Financial Results Conference Call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics first quarter 2023 financial results conference call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics Full Year 2022 financial results conference call and webcast.
12 Best 52-Week High Stocks To Buy Now
In this article, we will take a look at the 12 best 52-week high stocks to buy now.
10 Best Medical Stocks Under $10
In this article, we will discuss the 10 best medical stocks under $10.
5 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
In this piece, we will take a look at the top five best stocks to buy under $20 according to Jeremy Green's Redmile Group.
Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group
In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green's Redmile Group.
Were Hedge Funds Right About Amicus Therapeutics, Inc. (FOLD)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Selling Amicus Therapeutics, Inc. (FOLD)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
5 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
In this article, we discuss the 5 pharmaceutical stocks to buy under $20 according to Jeremy Green's Redmile Group portfolio based on Q3 holdings of the fund.
Top Investors’ Stock Portfolio: 5 Small-Cap Stocks To Buy
In this article, we discuss the best small-cap stocks to buy.
15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors.
10 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
In this article, we will discuss the 10 best biotech stocks to buy according to Joseph Edelman’s Perceptive Advisors.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider...
Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” first quarter 2021 investor letter – a copy of which can be ...
Is FOLD Stock A Buy or Sell?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Is FOLD A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
5 Best Biotech Stocks to Invest In
Below are the 5 best biotech stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman.
Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file ...
Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD)
We hate to say this but, we told you so.
2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD)
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about...
Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could...
Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed...
Hedge Fund and Insider Trading News: Warren Buffett, Elliott Management, Mcdonald’s Corp (MCD), GTT Communications Inc (GTT), Butler National Co. (BUKS), and More
Warren Buffett’s Berkshire Hathaway Inc. is hopping on the fintech bandwagon.
Hedge Fund and Insider Trading News: Ken Griffin, Carl Icahn, Howard Hughes Corp (HHC), Amicus Therapeutics, Inc. (FOLD), Falcon Minerals Corp (FLMN), and More
Billionaire Ken Griffin hired two veteran money managers from Louis Bacon’s hedge fund as he seeks to build a rival macro business.
Hedge Fund and Insider Trading News: Bill Miller, John Paulson, Warren Buffett, Amicus Therapeutics, Inc. (FOLD), Workday Inc (WDAY), and More
Famed investor Bill Miller is still a believer in Facebook. "This too will pass," he said in an email to CNBC's Scott Wapner.
Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S.
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Biotech Movers And Shakers: Nivalis Therapeutics Inc (NVLS) And Amicus Therapeutics, Inc. (FOLD)
It’s time to take a look at those stocks that really moved over the last twenty-four hours or so in biotech, and there are plenty to go at.
Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two Other Stocks?
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven or eight consecutive...
Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS)
While wider markets turn there focus to the US elections, the biotech space is alive and well, and after a tough end to last week, a number of companies have enjoyed gains throughout...
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
Five Cheap Healthcare Stocks Poised to Explode
The healthcare sector has witnessed a significant correction in the last 15 months, with many prominent names in the industry losing a noteworthy chunk of their market capitalization...
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
